Sales & Marketing News | pharmaphorum

News

Home

2023 PM Society Digital Awards, OPEN Health takes 3 Golds

Over the course of 14 years, the PM Society Digital Awards have cemented their place as a highlight on the healthcare marketing calendar.

News

FTC fires shot across pharma's bows over 'improper' patents

The financial regulator in the US has warned the pharma industry that it may consider legal action against companies that improperly list patents in the FDA's 'Orange Book

News

Alnylam's Onpattro clears FDA vote for ATTR-cardiomyopathy

Despite a sceptical appraisal by FDA reviewers, Alnylam's Onpattro has been recommended for approval as a treatment for transthyretin amyloidosis cardiomyopathy (ATTR-CM)

News

Oral phenylephrine vote may see OTC products pulled in US

An FDA advisory committee has concluded that a commonly used decongestant ingredient used in cold and allergy products does not have any efficacy, raising the possibility

News

EU clears review of Xtandi in earlier-stage prostate cancer

The EMA will kick off a review of Astellas and Pfizer's prostate cancer therapy Xtandi in an earlier-stage form of the cancer, which if approved could give the product a l

News

Leschly steps down as 2seventy wields the axe

2seventy bio is slashing 40% of its workforce to conserve cash as it tries to build momentum for its FDA-approved CAR-T therapy, while chief executive Nick Leschly is also

2023 PM Society Digital Awards, OPEN Health takes 3 Golds

FTC fires shot across pharma's bows over 'improper' patents

Alnylam's Onpattro clears FDA vote for ATTR-cardiomyopathy

Oral phenylephrine vote may see OTC products pulled in US

EU clears review of Xtandi in earlier-stage prostate cancer

Leschly steps down as 2seventy wields the axe

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

News

Editor's Picks